Literature DB >> 32606176

The Number of Harvested LNs Is an Independent Prognostic Factor in Lymph Node Metastasis-negative Patients Who Received Curative Esophagectomy.

Toru Aoyama1, Yosuke Atsumi2, Shinnosuke Kawahara2, Hiroshi Tamagawa2, Ayako Tamagawa2, Yukio Maezawa2,3, Kazuki Kano2, Masaaki Murakawa2, Keisuke Kazama2, Masakatsu Numata2, Takashi Oshima2,4, Norio Yukawa2, Munetaka Masuda2, Yasushi Rino2.   

Abstract

BACKGROUND/AIM: The aim of the present study was to evaluate the optimal number of harvested LNs (LNs) in patients who were LN metastasis-negative after curative esophagectomy for esophageal cancer. PATIENTS AND METHODS: Sixty-one patients who underwent curative surgery for esophageal cancer between 2005 and 2017 and diagnosed as lymph node metastasis-negative were included in this study.
RESULTS: The 5-year overall survival rates were 27.8% for 0-20 harvested LNs, 35.7% for 21-30 harvested LNs, 79.4% for 31-40 harvested LNs, and 85.2% for ≥41 harvested LNs. Thirty harvested LNs was regarded as the optimal critical point of classification, considering the 5-year OS rate. The number of harvested LNs was selected as a significant prognostic factor in both univariate and multivariate analyses. The respective 3- and 5-year OS rates were 50.3% and 36.7% for <30 harvested LNs and 82.4% and 82.4% for ≥30 harvested LNs (p=0.003).
CONCLUSION: Thirty or more harvested LNs was a significant prognostic factor in patients with metastasis-negative LNs after curative esophagectomy for esophageal cancer. Therefore, the number of harvested LNs might be useful for predicting the LN metastasis status in esophageal cancer. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Esophageal cancer; lymph node; recurrence; survival

Mesh:

Year:  2020        PMID: 32606176      PMCID: PMC7439900          DOI: 10.21873/invivo.12001

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  20 in total

1.  Negative lymph node at station 108 is a strong predictor of overall survival in esophageal cancer.

Authors:  Jinling Zhang; Xueyuan Heng; Yi Luo; Luning Li; Haiyan Zhang; Fengyuan Che; Baosheng Li
Journal:  Oncol Lett       Date:  2018-09-18       Impact factor: 2.967

2.  Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy.

Authors:  Jhe-Cyuan Guo; Chia-Chi Lin; Ta-Chen Huang; Pei-Ming Huang; Hung-Yang Kuo; Chin-Hao Chang; Chia-Chun Wang; Jason Chia-Hsien Cheng; Kun-Huei Yeh; Chih-Hung Hsu; Jang-Ming Lee
Journal:  Anticancer Res       Date:  2018-03       Impact factor: 2.480

3.  Lymph Node Ratio as a Risk Factor for Recurrence After Adjuvant Chemotherapy in Stage III Colorectal Cancer.

Authors:  Akira Ooki; Kiwamu Akagi; Toshimasa Yatsuoka; Masako Asayama; Hiroki Hara; Yoji Nishimura; Hiroshi Katoh; Keishi Yamashita; Masahiko Watanabe; Kensei Yamaguchi
Journal:  J Gastrointest Surg       Date:  2017-03-01       Impact factor: 3.452

4.  Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer.

Authors:  É J Ryan; D P O'Sullivan; M E Kelly; A Z Syed; P C Neary; P R O'Connell; D O Kavanagh; D C Winter; J M O'Riordan
Journal:  Br J Surg       Date:  2019-06-19       Impact factor: 6.939

5.  Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance.

Authors:  S B Hosch; N H Stoecklein; U Pichlmeier; A Rehders; P Scheunemann; A Niendorf; W T Knoefel; J R Izbicki
Journal:  J Clin Oncol       Date:  2001-04-01       Impact factor: 44.544

6.  Analysis of micrometastatic disease in histologically negative lymph nodes of patients with adenocarcinoma of the distal esophagus or gastric cardia.

Authors:  C J Buskens; F J W Ten Kate; H Obertop; J R Izbicki; J J B van Lanschot
Journal:  Dis Esophagus       Date:  2008       Impact factor: 3.429

7.  The Prognostic Value of the Number of Negative Lymph Nodes Combined with Positive Lymph Nodes in Esophageal Cancer Patients: A Propensity-Matched Analysis.

Authors:  Linghui Zhou; Yang Zhao; Yi Zheng; Meng Wang; Tian Tian; Shuai Lin; Qian Hao; Peng Xu; Yujiao Deng; Na Li; Ying Wu; Tielin Yang; Huafeng Kang; Zhijun Dai
Journal:  Ann Surg Oncol       Date:  2020-01-02       Impact factor: 5.344

8.  Role of Perioperative Chemotherapy in Lymph Node-negative Esophageal Cancer After Resection: A Population-based Study With Propensity Score-matched Analysis.

Authors:  Yang Yang; Xia Zhou; Luoyong Tang; Xiaoling Xu; Xianghui Du; Guoqin Qiu
Journal:  Am J Clin Oncol       Date:  2019-12       Impact factor: 2.339

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  The Significance of Negative Lymph Nodes in Esophageal Cancer After Curative Resection: A Retrospective Cohort Study.

Authors:  Junxian Mo; Dongni Chen; Changbo Li; Mingwu Chen
Journal:  Cancer Manag Res       Date:  2020-02-20       Impact factor: 3.989

View more
  2 in total

1.  Clinical Influence of the Lymph Node Ratio on Lymph Node Metastasis-positive Gastric Cancer Patients Who Receive Curative Treatment.

Authors:  Toru Aoyama; Kesikeu Komori; Ayako Tamagawa; Masato Nakazano; Kentaro Hara; Itaru Hashimoto; Hiroshi Tamagawa; Kenki Segami; Yukio Maezawa; Kazuki Kano; Takashi Oshima; Norio Yukawa; Yasushi Rino
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

2.  Number of Examined Lymph Nodes as a Risk Factor for Recurrence in pT1N+ or pT2-3N0 Gastric Cancer.

Authors:  Masato Nishimuta; Junichi Arai; Keiko Hamasaki; Yasumasa Hashimoto; Takashi Nonaka; Tetsuro Tominaga; Shosaburo Oyama; Toru Yasutake; Terumitsu Sawai; Takeshi Nagayasu
Journal:  Cancer Diagn Progn       Date:  2022-09-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.